REDWOOD CITY, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 13, 2019 , the compensation committee of the company’s board of directors granted the newly hired Chief Legal Officer an option to buy 225,000 shares of the

REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus’ legal

REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) biosimilar for transitional pass-through payment status in the hospital outpatient

REDWOOD CITY, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31 , 2018.  Fourth Quarter 2018 and Recent Corporate Highlights Include: On November 2, 2018

REDWOOD CITY, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the 38 th Cowen & Company Healthcare Conference

REDWOOD CITY, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 21, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 47,000 shares of the

REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on Thursday, February 28, 2019 . Starting at 4:30 p.m.

REDWOOD CITY, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 40,000 shares of the

Complaint alleges Amgen infringes three U.S. patents recently awarded to Coherus REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (

- The settlement affords U.S. market entry of December 15, 2023 - REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc.

REDWOOD CITY, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 68,000 shares of the

REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners .

REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton , M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019 . “We are very pleased that Dr.

REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37 th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco .